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Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in none
small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of
tumor tissue. This study evaluated the interlaboratory performance and reproducibility of a real-time
PCR EGFR mutation test (cobas EGFR Mutation Test v2) to detect EGFR variants in plasma. Fourteen
laboratories received two identical panels of 27 single-blinded plasma samples. Samples were wild type
or spiked with plasmid DNA to contain seven common EGFR variants at six predeﬁned concentrations
from 50 to 5000 copies per milliliter. The circulating tumor DNA was extracted by a cell-free circulating
DNA sample preparation kit (cobas cfDNA Sample Preparation Kit), followed by duplicate analysis with
the real-time PCR EGFR mutation test (Roche Molecular Systems, Pleasanton, CA). Lowest sensitivities
were obtained for the c.2156G>C p.(Gly719Ala) and c.2573T>G p.(Leu858Arg) variants for the lowest
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target copies. For all other variants, sensitivities varied between 96.3% and 100.0%. All speciﬁcities
were 98.8% to 100.0%. Coefﬁcients of variation indicated good intralaboratory and interlaboratory
repeatability and reproducibility but increased for decreasing concentrations. Prediction models
revealed a signiﬁcant correlation for all variants between the predeﬁned copy number and the observed
semiquantitative index values, which reﬂect the samples’ plasma mutation load. This study demon-
strates an overall robust performance of the real-time PCR EGFR mutation test kit in plasma. Prediction
models may be applied to estimate the plasma mutation load for diagnostic or research purposes.
(J Mol Diagn 2018, 20: 483e494; https://doi.org/10.1016/j.jmoldx.2018.03.006)
Lung cancer is the leading cause of cancer-related mortality
worldwide, with most being attributable to nonesmall cell
lung cancer (NSCLC) as its most common subtype.1
Approximately 10% to 20% of non-Asian patients with
advanced nonsquamous NSCLC present with variants in the
kinase domain of the EGFR gene.2 Tyrosine kinase inhibitors
(TKIs) that target activating variants in EGFR have demon-
strated strong effectiveness in the treatment of patients with
NSCLC.3,4 Therefore, molecular testing of EGFR in patients
with NSCLC is required by the European Medicines Agency
(http://www.ema.europa.eu, last accessed May 1, 2017) and
the US Food and Drug Administration (http://www.fda.gov,
last accessed May 1, 2017) and recommended by both the
European Society of Medical Oncology5 and the National
Comprehensive Cancer Network guidelines to predict
therapeutic response to ﬁrst- (geﬁtinib and erlotinib),
second- (afatinib), and third- (osimertinib) generation
TKIs.6 As a result, diagnostic laboratories are challenged to
meet these requirements, using reliable methods and
processes to ensure that patients receive a timely and
accurate report. To date, genotyping of formalin-ﬁxed,
parafﬁn-embedded (FFPE) tumor tissue for EGFR
alterations has become routine practice.7 Although routinely
performed, biopsy of tumor tissue is an invasive procedure
and presents substantial challenges, such as limited tissue
availability or intratumor and intertumor heterogeneity.8,9
To overcome these limitations, less invasive techniques
capable of capturing tumor heterogeneity and the molecular
changes cancer cells undergo when they are exposed to
therapy are desirable.10 During the last decade, testing of
liquid biopsy samples has shown promising results to
overcome some of these barriers. Liquid biopsy samples
can consist of almost all body ﬂuids (blood, serum, plasma,
urine, pleural effusion, ascites) and allow the extraction of
tumor DNA from circulating tumor cells, exosomes, and
cell-free circulating DNA (cfDNA). A variety of clinical
indications have been hypothesized for different solid
tumor types, including the prediction of treatment response
and the evaluation of prognosis, early detection of disease
recurrence, or the development of acquired resistance.11
Although the amount and quality of cfDNA obtained from
plasma samples can be challenging to work with, its
included cell-free tumor DNA (ctDNA) appears to be an
extremely effective and advantageous biomarker. Recent
technical developments have improved the diagnostic
accuracy of variants identiﬁed in ctDNA, and techniques
are available that allow monitoring of tumor-associated
genetic aberrations in plasma, such as real-time PCR, next-
generation sequencing (NGS), droplet-digital PCR
(ddPCR), or beads, emulsion, ampliﬁcation, magnetics
(BEAMing) PCR.12 The variation in EGFR detection rates
observed in prior studies with these methods highlights the
need for a sensitive, standardized method for blood-based
testing.13e17 For the available platforms for ctDNA analysis,
several key questions still need to be addressed, including
the sensitivity and speciﬁcity as well as clinical features
that may affect the sensitivity of EGFR analysis in plasma.
In June 2016, a real-time PCR EGFR mutation test (cobas
EGFR Mutation Test v2; Roche Molecular Systems Inc.,
Pleasanton, CA), hereafter referred to as the EGFRv2 test,
was approved by the US Food and Drug Administration as
a companion diagnostic for the detection of EGFR variants
in plasma (https://www.accessdata.fda.gov/cdrh_docs/pdf15/
P150047b.pdf and https://www.accessdata.fda.gov/cdrh_
docs/pdf15/P150047a.pdf, last accessed March 5, 2018).
Several individual studies on patient samples have
demonstrated the feasibility of this assay, a strong overall
agreement in EGFR results between plasma and FFPE
tissue, and a high concordance of plasma results with other
technologies, such as BEAMing and NGS.13e17 Our aims
were to evaluate the performance and reproducibility of the
kit to detect common EGFR variants in contrived plasma
samples among multiple test sites and to assess the
correlation of those results with the copy numbers of the
respective EGFR variants.
Material and Methods
Fourteen laboratories from 10 European countries were
included in the study based on their previous experience with
the EGFRv1, availability of necessary facilities, and a pre-
ceding survey on laboratory characteristics. To ensure
harmonization, test sites received a 2-day hands-on training for
cfDNA extraction and EGFR variant detection before the
study. Two obligatory proﬁciency samples needed to be
correctly identiﬁed, after which an operator qualiﬁcation letter
was issued that allowed the laboratory to proceed with testing.
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Table 1 Overview of the 27 Samples Included in the Plasma Panel, the EGFR Variants, and Their Respective Copy Numbers
Panel member EGFR variant Copy numbers (target copies/mL)
1 c.2235_2249del p.(Glu746_Ala750del)
c.2369C>T p.(Thr790Met)
100
2 Wild-type 0
3 c.2235_2249del p.(Glu746_Ala750del)
c.2369C>T p.(Thr790Met)
5000
4 c.2582T>A p.(Leu861Gln)
c.2307_2308ins p.(Val769_Asp770ins)
500
5 c.2573T>G p.(Leu858Arg)
c.2369C>T p.(Thr790Met)
50
6 c.2235_2249del p.(Glu746_Ala750del)
c.2369C>T p.(Thr790Met)
250
7 c.2303G>T p.(Ser768Ile)
c.2156G>C p.(Gly719Ala)
100
8 c.2573T>G p.(Leu858Arg)
c.2369C>T p.(Thr790Met)
1000
9 c.2573T>G p.(Leu858Arg)
c.2369C>T p.(Thr790Met)
500
10 Wild-type 0
11 c.2582T>A p.(Leu861Gln)
c.2307_2308ins p.(Val769_Asp770ins)
5000
12 c.2573T>G p.(Leu858Arg)
c.2369C>T p.(Thr790Met)
100
13 c.2573T>G p.(Leu858Arg)
c.2369C>T p.(Thr790Met)
5000
14 c.2573T>G p.(Leu858Arg)
c.2369C>T p.(Thr790Met)
250
15 c.2303G>T p.(Ser768Ile)
c.2156G>C p.(Gly719Ala)
50
16 Wild-type 0
17 c.2235_2249del p.(Glu746_Ala750del)
c.2369C>T p.(Thr790Met)
1000
18 c.2582T>A p.(Leu861Gln)
c.2307_2308ins p.(Val769_Asp770ins)
50
19 c.2582T>A p.(Leu861Gln)
c.2307_2308ins p.(Val769_Asp770ins)
250
20 c.2235_2249del p.(Glu746_Ala750del)
c.2369C>T p.(Thr790Met)
50
21 c.2582T>A p.(Leu861Gln)
c.2307_2308ins p.(Val769_Asp770ins)
100
22 c.2303G>T p.(Ser768Ile)
c.2156G>C p.(Gly719Ala)
5000
23 c.2303G>T p.(Ser768Ile)
c.2156G>C p.(Gly719Ala)
500
24 c.2303G>T p.(Ser768Ile)
c.2156G>C p.(Gly719Ala)
250
25 c.2303G>T p.(Ser768Ile)
c.2156G>C p.(Gly719Ala)
1000
26 c.2582T>A p.(Leu861Gln)
c.2307_2308ins p.(Val769_Asp770ins)
1000
27 c.2235_2249del p.(Glu746_Ala750del)
c.2369C>T p.(Thr790Met)
500
Each test site received two identical plasma panels. Plasma samples are wild-type or contained a combination of two EGFR variants. Note that the c.2369C>T
p.(Thr790Met) variant is present in two combinations, once with the exon 19 deletion c.2235_2249del p.(Glu746_Ala750del) variant (panel members 1, 3, 6,
17, 20, and 27) and once with the c.2573T>G p.(Leu858Arg) variant (panel members 5, 8, 9, 12, 13, and 14). For each panel member, two runs (A and B) were
performed. Samples were generated and pretested with next-generation sequencing by Roche Molecular Systems (Pleasanton, CA).
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Between January andMarch 2016, the test sites received two
identical panels of 27 single-blinded samples that contained 4.2
mL of plasma each. Sample generation and subsequent
conﬁrmation of the copy numbers were performed by Roche
Molecular Systems. Samples were generated by using normal
(healthy donor) plasma in K2 EDTA tubes that were pretested
by the EGFRv2 kit to be negative for any of theEGFR variants,
after which nonsheared, linearized plasmids with an approxi-
mate size of 3.2 kbwere spiked in. Copynumber determination
was performed by optical density testing (J.F.P., P.M.W., S.S.,
N.N., J.H.v.K.,A.S, F.F., D.G.d.C., S.H., I.K., F.L-R.,M.D.L.,
A.M., P.H., E.S., U.S., B.S., P.T., M.T., H.V., and E.M.C.D.)
and conﬁrmed by comparing to the EGFRv2 standard curve
and NGS (in-house developed panel on MiSeq platform, Illu-
mina, San Diego, CA). The limit of detection (LOD) of the
EGFRv2 kit has previously been deﬁned by the manufacturer.
Samples were shipped on dry ice and stored at 80C
before further analyses. The panels included three EGFR
wild-type cases along with 24 cases of human plasma,
spiked with plasmid DNA that contained seven common
EGFR variants at six predeﬁned target copies per milliliter
(Table 1).
The cfDNA was extracted from the plasma by the a cell-
free circulating DNA sample preparation kit (cobas cfDNA
Sample Preparation Kit, Roche Molecular Systems) ac-
cording to the manufacturer’s protocol (https://www.
Figure 1 Overview of the testing algorithm
followed by the laboratories to analyze two iden-
tical 27-plasma member (PM) panels in duplicate,
yielding a total of four runs per PM.
Table 2 Analytical Sensitivity and Speciﬁcity of the EGFRv2 Test to Identify Seven EGFR Variants in Cell-Free Tumor DNA Derived From Plasma
Copy number
(copies/mL)
c.2235_2249del
p.(Glu746_Ala750del)
Number
of tests
c.2369C>T
p.(Thr790Met)
Number
of tests
c.2573T>G
p.(Leu858Arg)
Number
of tests
Sensitivity
50 100.0 (93.6e100.0) 56 96.3 (90.9e99.0) 109 88.7 (77.0e95.7) 53
100 100.0 (93.5e100.0) 55 100.0 (96.6e100.0) 108 98.1 (89.9e100.0) 53
250 100.0 (93.6e100.0) 56 99.1 (95.0e100.0) 110 98.1 (90.1e100.0) 54
500 100.0 (93.6e100.0) 56 100.0 (96.8e100.0) 112 98.2 (90.4e100.0) 56
1000 100.0 (93.6e100.0) 56 100.0 (96.8e100.0) 112 98.2 (90.4e100.0) 56
5000 100.0 (93.6e100.0) 56 100.0 (96.8e100.0) 112 98.2 (90.4e100.0) 56
Mean 100.0 (98.9e100.0) 335 99.2 (98.2e99.8) 663 96.6 (94.1e98.3) 328
Speciﬁcity
0 100.0 (97.8e100.0) 166 100.0 (98.9e100.0) 332 100.0 (97.8e100.0) 166
50 100.0 (97.8e100.0) 164 100.0 (98.9e100.0) 331 100.0 (97.8e100.0) 167
100 100.0 (97.8e100.0) 165 100.0 (98.9e100.0) 332 100.0 (97.8e100.0) 167
250 99.4 (96.7e100.0) 165 100.0 (98.9e100.0) 332 100.0 (97.8e100.0) 167
500 100.0 (97.8e100.0) 167 100.0 (98.9e100.0) 334 100.0 (97.8e100.0) 167
1000 100.0 (97.8e100.0) 167 100.0 (98.9e100.0) 334 100.0 (97.8e100.0) 167
5000 100.0 (97.8e100.0) 168 100.0 (98.9e100.0) 336 100.0 (97.8e100.0) 168
Mean 99.9 (99.5e100.0) 1162 100.0 (99.8e100.0) 2331 100.0 (99.8e100.0) 1169
(table continues)
The exact 95% CIs are given in parenthesis. Underlined values are those observed at the kit’s limit of detection. The number of tests represent the four tests
performed (duplicate analysis of two identical panels) for a given variant by all 14 test sites, excluding runs during which a technical failure or protocol deviation
occurred. Number of runs are higher for the c.2369C>T p.(Thr790Met) variant because of its presence in two combinations of EGFR variants included in the plasma
panel.
Keppens et al
486 jmd.amjpathol.org - The Journal of Molecular Diagnostics
accessdata.fda.gov/cdrh_docs/pdf15/p150047c.pdf, last
accessed March 5, 2018). Subsequently, each sample was
subjected to duplicate analysis with the EGFRv2 test
according to the manufacturer’s instructions. The EGFRv2
assay applies real-time PCR for the detection of 42 EGFR
variants in exons 18, 19, 20, and 21 in both plasma and
FFPE tissue18 with a LOD of at least 100 copies/mL of
plasma (Supplemental Table S1).
To determine the LOD (https://www.accessdata.fda.gov/
cdrh_docs/pdf15/p150047c.pdf, last accessed March 5,
2018), sheared cell line DNA that contained each of the
seven mutation classes detected by the test were added to
healthy donor K2 EDTA plasma that was wild-type for
EGFR. Serial dilutions were prepared and 24 replicates of
each panel member were tested, using each of three
EGFRv2 kit lots. The LOD was determined for each of
the seven mutation classes detected by the test as the
lowest concentration of DNA yielding an EGFR mutation
detected rate of at least 95% for the targeted mutation.
This study demonstrated that the EGFRv2 kit can detect
mutations in EGFR exons 18, 19, 20, and 21 with 100
copies/mL of mutant DNA using the standard input of 25
mL of DNA stock per reaction well. The mean size of the
sheared DNA was 220 bp, in line with the size of the
DNA found in plasma.
Analyses were performed across four subsequent test
days (Figure 1). Samples were analyzed automatically by
the EGFR Plasma Analysis Package Software version
1.0 (Roche Molecular Systems) in combination with the
cobas z480 analyzer with software version 2.1 (Roche
Molecular Systems), after which an automated report
was generated. Laboratories could request an additional
plasma panel for testing with an alternate method, such as
ddPCR.
In case an EGFR variant was detected in the sample, the
software automatically reports a corresponding semi-
quantitative index (SQI) value. This SQI is determined by
using the observed Ct and a proprietary, unique algorithm
for that speciﬁc variant. The SQI value correlates with the
target copies per milliliter and is independent of the amount
of background DNA, as opposed to the mutant allele
frequencies.
An electronic database was set up to collect all results,
that allowed the reporting of protocol deviations and the
uploading of the automated reports, and included questions
on additional testing variables. These data were collected
and analyzed independently by the Biomedical Quality
Assurance Research Unit (University of Leuven, Leuven,
Belgium). Statistical analyses were performed with SAS
version 9.4 (SAS Institute Inc., Cary, NC) in collaboration
with the Leuven Biostatistics and Statistical Bioinformatics
Center (University of Leuven). Graphs were generated using
GraphPad Prism version 7.0 (GraphPad Software Inc., La
Jolla, CA).
Results
Of the 14 test sites included in the study, nine of the labora-
tories were located in a university hospital, two in a com-
munity hospital, two in a private laboratory, and one in a
Table 2 (continued)
c.2156G>C
p.(Gly719Ala)
Number
of tests
c.2303G>T
p.(Ser768Ile)
Number
of tests
c.2582T>A
p.(Leu861Gln)
Number
of tests
c.2307_2308ins
p.(Val769_Asp770ins)
Number
of tests
80.4 (67.6e89.8) 56 100.0 (93.6e100.0) 56 100.0 (93.5e100.0) 55 100.0 (93.5e100.0) 55
69.6 (55.9e81.2) 56 100.0 (93.6e100.0) 56 100.0 (93.6e100.0) 56 100.0 (93.6e100.0) 56
89.1 (77.8e95.9) 55 100.0 (93.5e100.0) 55 100.0 (93.6e100.0) 56 100.0 (93.6e100.0) 56
98.2 (90.4e100.0) 56 100.0 (93.6e100.0) 56 100.0 (93.5e100.0) 56 100.0 (93.5e100.0) 56
98.2 (90.3e100.0) 55 100.0 (93.5e100.0) 55 100.0 (93.6e100.0) 55 100.0 (93.6e100.0) 55
100.0 (93.6e100.0) 56 100.0 (93.6e100.0) 56 100.0 (93.6e100.0) 56 100.0 (93.6e100.0) 56
89.2 (85.4e92.3) 334 100.0 (98.9e100.0) 334 100.0 (98.9e100.0) 334 100.0 (98.9e100.0) 334
100.0 (97.8e100.0) 166 100.0 (97.8e100.0) 166 100.0 (97.8e100.0) 166 100.0 (97.8e100.0) 166
100.0 (97.8e100.0) 164 100.0 (97.8e100.0) 164 100.0 (97.8e100.0) 165 100.0 (97.8e100.0) 165
98.8 (95.7e99.9) 164 100.0 (97.8e100.0) 164 100.0 (97.8e100.0) 164 100.0 (97.8e100.0) 164
100.0 (97.8e100.0) 166 100.0 (97.8e100.0) 166 100.0 (97.8e100.0) 165 100.0 (97.8e100.0) 165
100.0 (97.8e100.0) 167 100.0 (97.8e100.0) 167 100.0 (97.8e100.0) 168 100.0 (97.8e100.0) 168
100.0 (97.8e100.0) 168 99.4 (96.7e100.0) 168 100.0 (97.8e100.0) 167 100.0 (97.8e100.0) 167
100.0 (97.8e100.0) 168 100.0 (97.8e100.0) 168 98.8 (95.8e99.9) 168 100.0 (97.8e100.0) 168
99.8 (99.4e100.0) 1163 99.9 (99.5e100.0) 1163 99.8 (99.4e100.0) 1163 100.0 (99.8e100.0) 1163
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cancer research institute. Ten of the 14 laboratories were also
performing research besides diagnostic EGFR analyses. At
the time of the survey, seven of the 14 test sites were
accredited for molecular pathology by conforming to
ISO15189 or equivalent national standards, and forﬁve others
accreditation was under way. However, analysis of liquid
biopsy samples was not yet required to attain accreditation.
Ten test sites reported having previous experience with
ctDNAanalysis, two in a diagnostic setting, three in a research
setting, and ﬁve in both. The other four laboratories were
planning to implement ctDNA analysis of plasma samples in
the near future. Eleven of the 14 test sites were able to
correctly identify both the EGFR c.2303G>T p.(Ser768Ile)
and c.2156G>C p.(Gly719Ala) variants present in the
two proﬁciency samples on the ﬁrst run. Three other test sites
succeeded after requesting a second set of samples (data not
shown).
For the two plasma panels included in the study, runs
were considered valid if the mutant and negative control
included in the kit were valid. Invalid sample results were
ﬂagged by the kit’s software. Test sites were asked to report
any deviation from the manufacturer’s protocol, which may
lead to a result that is not considered reliable. Results dis-
played no failed overall runs; however, on an individual
sample level, 3 of 1512 technical failures (0.2%) were
observed, meaning that no information on the EGFR status
could be obtained for this sample. Protocol deviations
occurred in 12 of 1512 tests (0.8%). Samples for which a
technical failure or protocol deviation occurred were
excluded from further statistical analyses.
To estimate the analytical sensitivity and speciﬁcity of the
kit, all four runs from each of the 14 laboratories were taken
into account for a given panel member, with the exclusion
of the results mentioned above. The sensitivity was calcu-
lated as the proportion of correctly identiﬁed variants (ie, the
number of test samples in which the variant was detected
divided by the number of test samples with the variant
present). Speciﬁcity was deﬁned as the proportion of
correctly identiﬁed wild-type samples (ie, the number of test
samples in which the variant was not detected divided by the
number of test samples without the variant). Calculated
sensitivities and speciﬁcities are represented in Table 2.
Taking into account all seven variants and predeﬁned copy
numbers, our results showed a sensitivity of 98.0% (95%
CI, 97.4%-98.5%) and a speciﬁcity of 99.9% (95% CI,
99.9%-100.0%). In 52 of the 2662 tests (2.0%), a false-
negative result was reported. A large fraction (40.4%) of
those false-negative results were observed at the lowest
copy number of 50 copies/mL for all EGFR variants com-
bined. The number of false-negative results decreased for
increasing copy numbers and hence resulted in an increased
sensitivity for higher copy numbers. In addition, most false-
negative results occurred for the c.2156G>C p.(Gly719Ala)
(69.2%) and c.2573T>G p.(Leu858Arg) (21.2%) variants.
No correlation was observed between the percentage of
false-negative results and a speciﬁc plasma sample or test
site. In contrast to false-negative results, a false-positive
result occurred in only 6 of the 9314 tests performed
(0.06%). Moreover, none of these results were reported for
any of the wild-type samples but were detected as an
additional variant in a case for which an EGFR variant was
already correctly identiﬁed. There was no correlation be-
tween the panel member, test site, copy number, or variant
and the false-positive results.
Figure 2 CV showing the extent of semiquantitative index
variability in relation to the mean (calculated as the ratio of SD
and the mean and expressed as a percentage). A: Intra-
laboratory repeatability expressed as CV for the different EGFR
variants and copy numbers (in copies per milliliter). The mean
CV for all 14 test sites is given. B: Interlaboratory reproduc-
ibility expressed as CV for the different EGFR variants and copy
numbers. The mean CV for four test repetitions is given.
C: Intratest day repeatability expressed as CV for the different
EGFR variants and copy numbers. The mean CV for all laboratory
and test day combinations is given.
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Sensitivities were the lowest for c.2369C>T
p.(Thr790Met), c.2573T>G p.(Leu858Arg), and
c.2156G>C p.(Gly719Ala) variants at 50 copies/mL
(Table 2), which is below the kit’s LOD (Supplemental
Table S1). For c.2156G>C p.(Gly719Ala), sensitivities
were lower at 100 and 250 copies/mL compared with
samples with higher copy numbers for that variant. Speci-
ﬁcities all exceeded 98.8% for all variants and copy
numbers tested.
For every EGFR variant detected by the kit software, a
corresponding SQI value is reported, which is speciﬁc for a
given variant and reﬂects the potential mutation load in the
sample. To evaluate the concordance of the SQI value
within and among test sites, the extent of variability was
deﬁned in relation to the mean and expressed in percentage.
This value, the CV, is represented in Figure 2 for every
variant and copy number. The intralaboratory repeatability
is deﬁned as the CV among the four tests obtained within a
single laboratory for that sample. The mean CV for all
laboratories is presented in Figure 2A. In contrast, the
interlaboratory reproducibility is quantiﬁed as the CV in test
results obtained among the different test sites. The mean CV
for the four tests is presented in Figure 2B. These results
demonstrated overall low CVs for all variants, although
increasing for lower copy numbers. Intralaboratory CVs
were all lower compared with interlaboratory CVs because
those tests were performed by the same operator. For
intralaboratory repeatability and interlaboratory reproduc-
ibility, CVs were higher at all copy numbers for the
c.2156G>C p.(Gly719Ala) variant compared with other
variants, with a maximum value of 26.3% at 50 copies/mL.
To calculate the intralaboratory and interlaboratory CVs, the
four tests were considered as measurements under equal
conditions. However, for every panel member, the ﬁrst two
runs (panel 1) were performed on the same test day, whereas
the last two runs (panel 2) were performed on another test
day (Figure 1). To explore whether the test day or panel
adds additional variability, the intralaboratory repeatability
was recalculated per laboratory and per test day, and the
mean for all laboratory and test day combinations is repre-
sented in Figure 2C. The intralaboratory CVs were slightly
lower compared with those in Figure 2A.
To evaluate the correlation between the SQI value and the
corresponding copy number of a variant, log-linear models
were used for the prediction of the target copy numbers based
on SQI values. A random intercept by laboratory was used to
account for clustering. The strength of the model was quan-
tiﬁed by the Pearson correlation coefﬁcient between the
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Figure 3 Estimated curves of model-predicted copy numbers (number of target copies per milli-
liter) by semiquantitative index (SQI) value with 95% CIs (dashed lines) overlaid with scatterplots of
observed SQI values. False-positive results, technical failures, and protocol deviations were excluded.
All curves show a log-linear association of Exp(a þ b  SQI). A Pearson correlation was performed
between observed and predicted copy numbers and showed all P < 0.0001. A: c.2235_2249del
p.(Glu746_Ala750del): a Z 4.462 (4.771; 4.154), b Z 0.661 (0.647; 0.676), r Z 0.989.
B: c.2303G>T p.(Ser768Ile): a Z 0.210 (0.472; 0.052), b Z 0.740 (0.720; 0.759), r Z 0.977.
C: c.2156G>C p.(Gly719Ala): a Z 2.800 (2.606; 2.994), b Z 0.658 (0.638; 0.679), r Z 0.988.
D: c.2573T>G p.(Leu858Arg): aZ 0.640 (1.132; 0.147), bZ 0.618 (0.587; 0.648), rZ 0.966.
E: c.2369C>T p.(Thr790Met): aZ 1.192 (1.495; 0.889), bZ 0.587 (0.571; 0.604), rZ 0.965.
F: c.2582T>A p.(Leu861Gln): a Z 1.433 (1.175; 1.691), b Z 0.683 (0.660; 0.705), r Z 0.951.
G: c.2307_2308ins p.(Val769_Asp770ins): a Z 2.534 (2.248; 2.821), b Z 0.615 (0.589; 0.641),
r Z 0.950.
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predeﬁned copy numbers and the model-predicted values.
Results revealed a nonlinear association of the following form:
exp(a þ b  SQI) (Figure 3), meaning that for a 1-unit
increase in the observed SQI value, the predicted copy
number in the sample will multiply by the exponential factor
b. In addition, there was a signiﬁcant (all P < 0.0001)
correlation between observed and predicted concentration
for all seven variants, with correlation coefﬁcients that
exceeded r Z 0.950, indicating that copy numbers can be
estimated based on the observed SQI values. In addition to
those ﬁndings, an analysis of variance was applied to the
model residuals to check the presence of a systematic pre-
diction error (overestimation or underestimation) by copy
number. The bias amount, direction, and corresponding
P values are represented in Table 3 and displayed a sig-
niﬁcant prediction bias for ﬁve of seven EGFR variants
included in the study. For those variants, an overestimation
of the predicted copy numbers was apparent at 1000 copies/
mL compared with a systematic underestimation at 5000
copies/mL. For the c.2369C>T p.(Thr790Met) and
c.2307_2308ins p.(Val769_Asp770ins) variants, an over-
estimation at 250 and 500 copies/mL was also observed. No
bias was detected at 50 and 100 copies/mL, respectively.
Finally, Levene’s test was used to test for differences in
variability of prediction error by copy number (Table 3).
Graphs for each of the seven variants demonstrate a higher
model residual variability (more prediction uncertainty or
error) for increasing copy numbers for all variants
(Supplemental Figure S1).
Besides the EGFRv2 test, the test sites were allowed to
request an additional plasma panel for analysis by amethod of
choice. One laboratory analyzed all 27 plasmamembers using
Sanger sequencing, and two others performed ddPCR on a
subset of plasma samples. Allelic frequencies detected by
ddPCR all correlated well with predeﬁned target copies (all
P < 0.0001, Pearson r > 0.93) but to a lesser extent with the
EGFRv2 SQI values reported by the same operator (all
P< 0.05, Pearson r> 0.80). Because of the limited amount of
data, results of these tests compared with the EGFRv2 test
results are represented in Supplemental Tables S2, S3, and S4.
Discussion
Accurate identiﬁcation of EGFR variants within an
acceptable timeframe is critical to select appropriate
therapy options for patients with advanced nonsquamous
NSCLC. Although analysis of FFPE tissue currently re-
mains the gold standard, the use of ctDNA in plasma as a
surrogate sample type has shown promising results, and
many laboratories are currently implementing this tech-
nique into research or diagnostic setting.19 The aim of this
study was threefold: i) to evaluate the performance of the
EGFRv2 test to detect common EGFR variants in plasma
Table 3 Model Residual Variability and Prediction Bias
EGFR variant
Residual
variability
(P value)
Prediction
bias
(P value)
Mean bias (95% CI)
50 copies/mL 100 copies/mL 250 copies/mL 500 copies/mL 1000 copies/mL 5000 copies/mL
c.2235_2249del
p.(Glu746_
Ala750del)
0.0235 0.1298 d d d d d d
c.2303G>T
p.(Ser768Ile)
<0.0001 0.0518 d d d d d d
c.2156G>C
p.(Gly719Ala)
<0.0001 0.0074 10.0 (79.0
to 59.0)
P Z 0.7748
1.1 (71.2
to 73.4)
P Z 0.9767
17.2 (48.9
to 83.4)
P Z 0.6082
16.5 (46.0
to 78.9)
P Z 0.6043
102.6 (165.6
to 39.6)
P [ 0.0015
72.2 (10.3
to 134.0)
P [ 0.0223
c.2573T>G
p.(Leu858Arg)
<0.0001 0.0005 23.2 (138.7
to 92.3)
P Z 0.6929
45.1 (154.8
to 64.7)
P Z 0.4198
20.6 (129.3
to 88.1)
P Z 0.7098
45.8 (152.5
to 60.9)
P Z 0.3991
124.6 (231.3
to 17.8)
P [ 0.0223
217.3 (110.5
to 324.0)
P< 0.0001
c.2582T>A
p.(Leu861Gln)
0.0004 <0.0001 19.7 (141.4
to 102.1)
P Z 0.7507
32.9 (153.5
to 87.8)
P Z 0.5922
62.2 (182.9
to 58.5)
P Z 0.3113
112.8 (234.5
to 9.0)
P Z 0.0693
129.5 (250.1
to 8.8)
P [ 0.0355
304.5 (185.9
to 423.0)
P< 0.0001
c.2369C>T
p.(Thr790Met)
<0.0001 <0.0001 20.6 (86.5
to 45.2)
P Z 0.5385
32.9 (97.9
to 32.0)
P Z 0.3199
86.1 (150.7
to 21.4)
P [ 0.0091
106.5 (170.2
to 42.7)
P [ 0.0011
228.6 (292.4
to 164.8)
P< 0.0001
180.6 (116.8
to 244.4)
P< 0.0001
c.2307_2308ins
p.(Val769_
Asp770ins)
<0.0001 <0.0001 63.6 (165.8
to 38.7)
P Z 0.2223
90.5 (191.9
to 10.8)
P Z 0.0798
173.7 (275.0
to 72.3)
P [ 0.0008
220.6 (322.9
to 118.3)
P [<0.0001
191.5 (292.9
to 90.2)
P [ 0.0002
225.7 (124.3
to 327.0)
P< 0.0001
Column 2: Levene’s test to evaluate model residual variability of prediction error depending on concentration. Signiﬁcance level aZ 0.05. For all variants,
more variability of prediction error was observed. Variability was higher for increasing copy numbers (data not shown). Column 3: Analysis of variance to
indicate systematic prediction bias depending on concentration. Signiﬁcance level aZ 0.05. Columns 4 through 7: Amount and direction of bias predicted in
column 3 for different copy numbers with 95% CIs. P < 0.05 indicates whether bias if different from zero. Mean bias <0 indicates overestimation. Mean bias
>0 indicates underestimation. Signiﬁcant results are shown in bold. Blank cells (d) represent copy numbers for which the direction of bias was not further
evaluated because no bias was detected.
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samples, ii) to evaluate the assay reproducibility among
multiple test sites, and iii) to assess the correlation of
those results with the copy numbers of the respective
EGFR variants.
Results for the ﬁrst goal demonstrate an overall robust
performance of the EGFRv2 test to correctly detect the
seven EGFR variants at predeﬁned target copies in
plasma, with an analytical sensitivity of 98.0% and
speciﬁcity of 99.9%. Previously, several groups have re-
ported an overall sensitivity and speciﬁcity of >72% and
>96% to correctly identify EGFR variants in plasma.13e15
However, it must be kept in mind that these were indi-
vidual studies using patient samples and that the mass of
cfDNA is variable.17 In this study, linearized plasmids
were spiked into plasma to assess the sensitivity and
speciﬁcity at various ranges of target copy numbers.
Although the size of the DNA present in the panels might
differ from patient samples, this set-up allowed us to
include an exact amount of ampliﬁable mutant copy
numbers. Namely, shearing the DNA to be more repre-
sentative of clinical samples would physically damage the
DNA and alter the ampliﬁable DNA and thus also the
ampliﬁable copy numbers. This set-up resulted in the
ability not only to evaluate the kit’s performance and
reproducibility at speciﬁc levels of target copies but also
to correlate these speciﬁc target copies to the obtained
SQI values. It might be advisable to compare sensitivities
of this study with those measured in patient samples;
however, this set-up was favorable to assess the repro-
ducibility of the kit between and within multiple test sites,
which might be more difﬁcult to reproduce with patient
material, which is limited.
Not surprisingly, most false-negative results occurred at
the lowest concentrations of 50 and 100 copies/mL. This
ﬁnding corresponds with the LOD deﬁned by the manu-
facturer of at least 100 copies/mL of mutant DNA (when
using the standard input of 25 mL of DNA stock per re-
action well). On a variant level, most false-negative results
were observed for the c.2156G>C p.(Gly719Ala), which is
not surprising because its LOD has previously been deﬁned
to be higher compared with the other variants (Table 3).
Previously, lower sensitivities have also been reported in
the literature for the detection of c.2156G>C
p.(Gly719Ala), c.2573T>G p.(Leu858Arg), and
c.2369C>T p.(Thr790Met) in patient samples.13e16
Nevertheless, in this study, the overall results were
acceptable, with mean sensitivities of 89.2%, 96.6%, and
99.2% and mean speciﬁcities of 99.8%, 100.0%, and 100%
for these three variants, respectively, disregarding the copy
numbers. In addition, detection of the other EGFR variants
at the LOD showed an acceptable sensitivity and speci-
ﬁcity, and no correlation was detected between the error
percentage and a speciﬁc plasma sample or test site.
Detection of the c.2369C>T p.(Thr790Met) variant at the
lowest target copies of 50 copies/mL yielded a sensitivity
of 96.3%. Detection of this variant at even low copies is
important because it has been described to occur at low
frequencies, confers acquired resistance to ﬁrst- and
second-generation EGFR TKI treatment, and is required
for testing before administration of a third-generation TKI,
such as osimertinib.20,21 In addition, detection of high copy
numbers demonstrated the performance of the kit without
the risk of saturation of the PCR.
Besides false-negative results, false-positive results are of
equal importance because both can have implications on
treatment selection and patient outcome. In this study, only
0.06% of false-positive results were observed of which none
were in wild-type samples but only as an additional variant
in a sample that already contained two EGFR variants. In
addition, none of the false-positive results included the
c.2369C>T p.(Thr790Met) variant, so clinical indications
would not be compromised. The fact that few false-positive
results were observed could be explained by the kit’s se-
lective ampliﬁcation process using the AmpErase (uracil-N-
glycosylase enzyme) enzyme, reducing the possibility of
PCR contamination.18
The second aim of this study was to evaluate the intra-
laboratory repeatability among the SQI values detected
during the four different runs for every variant and con-
centration, as well as the interlaboratory reproducibility of
this value among the 14 different test sites. This value
correlates with the mutation load in a sample so that
sequentially collected samples can be used to monitor
changes in ctDNA during a speciﬁed period.18 Results
revealed that the SQI variability is acceptable but increases
for lower copy numbers for all EGFR variants. Therefore, it
may be useful to perform duplicate tests during validation to
reduce the mean variation. Not surprisingly, interlaboratory
CVs are higher compared with intralaboratory CVs because
tests are performed by different operators. The small dif-
ference with the intratest day CV suggests that the test day
or panel accounts for only limited additional variability
among the SQI values reported by the same test operator.
Strikingly, CVs are higher for the c.2156G>C
p.(Gly719Ala) variant compared with all other variants.
Although detection of this variant seems to be more difﬁcult
compared with others, CVs are within an acceptable
range,22 and the variant was always detected in at least one
of the four runs.
The third aim of this study looked at the correlation of the
SQI values with the predeﬁned copy numbers, which
revealed three interesting ﬁndings. First, there was a strong
nonlinear association between the reported SQI values and
the predeﬁned target copies (Figure 3). Although this study
used contrived plasma samples, Pearson correlation co-
efﬁcients between the SQI value and the percentage of
EGFR variant measured by NGS were previously reported
for patient samples for c.2235_2249del p.(Glu746_
Ala750del), c.2573T>G p.(Leu858Arg), and c.2369C>T
p.(Thr790Met)15 and were of the same order as results
observed during this study. The resulting curves can be
applied by future kit users to determine the copy number of
Performance of EGFR Detection in Plasma
The Journal of Molecular Diagnostics - jmd.amjpathol.org 491
EGFR variants in plasma samples, which could have ben-
eﬁts in both diagnostics and research.
For instance, the ratio of the resistance and the sensitizing
variants could help in selecting those patients who have a
higher probability of beneﬁting from treatment with drugs
targeting c.2369C>T p.(Thr790Met).21,23 In addition,
methods that allow estimating the mutation load in a sample
could contribute to understanding the link between mutation
load and tumor progression or treatment response to TKIs.
However, the reproducibility and correlation to the SQI
values should be validated in real patient material before
using the data for interpretation of clinical samples.
Second, scatterplots of model residuals by concentration
(Supplemental Figure S1) showed that all variants display a
higher variability of prediction error for increasing con-
centrations (Table 3). This means that for higher copy
numbers, the difference between the observed and predicted
concentration becomes larger. On the basis of the intrinsic
properties of an exponential association, an identical in-
crease in SQI value will result in a larger difference between
predicted copy numbers for higher observed SQI values.
Third, for all variants besides the c.2235_2249del
p.(Glu746_Ala750del) and c.2303G>T p.(Ser768Ile), there
was a systematic prediction bias that resulted in an under-
estimation at 1000 copies/mL and overestimation of the
mutation load in the samples at 5000 copies/mL. This
ﬁnding is not surprising because the inclusion of the 5000
copies/mL has skewed the curve in its direction. Therefore,
it is important to take into account these systematic errors in
Table 2 when calculating the predicted mutation load in the
sample based on the curves and formula represented in
Figure 2. The amount of ctDNA obtained in real patient
samples is highly variable because it is linked to the pa-
tient’s treatment and underlying biology and the exact
ranges in which variants tend to occur still remain to be
determined. Although the exact mutation load might be
important for applications such as the early detection of
resistance mechanisms, the qualitative detection of EGFR
variants is currently the only requirement to inform the
clinician about the likelihood of response to TKI therapy.
Finally, EGFR variants can be detected in ctDNA using a
variety of methods, including real-time PCR, NGS, and
ddPCR.21,23 Because ctDNA is present at low concentra-
tions, its detection requires highly sensitive techniques. One
of the main advantages of the EGFRv2 test is that it is an
efﬁcient process to detect EGFR variants in plasma and to
guide appropriate therapy options in patients with NSCLC,
within an acceptable turnaround time. The fact that only a
few technical errors occurred and that 14 test sites with
different characteristics were able to successfully pass pro-
ﬁciency testing suggests the ease of implementing this
method in the laboratory, although keeping in mind the
previous working experience of the test sites with the
EGFRv1 kit. Both in the IQNPath 2016 ctDNA pilot EQA
scheme and the ESP 2016 Lung EQA scheme, adequacy of
the EGFRv2 kit was also shown in both plasma and tissue
material, with only a small percentage of false-positive or
false-negative results (<3%) and no technical failures (un-
published data). Although commercial kits have the disad-
vantage that they are not able to determine the variant allele
frequency, the curves described above allow users to esti-
mate the mutation load in the plasma based on the SQI
value. Although the variant allele frequency is dependent on
the amount of background DNA in the sample, this is not
the case for a sample’s mutation load. However, to date,
reporting of the SQI value is only available in the EGFRv2
kit with a European in vitro diagnostic label. In the United
States, SQI values are provided for research use only but not
for the US in vitro diagnostic labeled kit.
Although targeted kits, such as the EGFRv2, detect only
known variants by using exact probes and their multiplexing
capability is limited compared with NGS, their analytical
sensitivity is higher, and turnaround time is signiﬁcantly
faster. In this study, a high concordance was observed be-
tween the EGFRv2 kit and ddPCR but to a lesser extent with
Sanger on testing of an additional plasma panel
(Supplemental Tables S1, S2, and S3). Previously, a high
concordance has also been described between the EGFRv2
kit and BEAMing14 or ultradeep NGS15 for the
c.2235_2249del p.(Glu746_Ala750del), c.2573T>G
p.(Leu858Arg), and c.2369C>T p.(Thr790Met) variants.
Not surprisingly, many samples had false-negative results
by Sanger sequencing because of the low sensitivity of 20%
to detect EGFR variants in ctDNA.
Conclusion
A number of prior studies have investigated the use of
ctDNA to deﬁne the EGFR status with varying results.13e17
This study demonstrates that the EGFRv2 test in combina-
tion with the cfDNA Sample Preparation Kit is a reliable
and reproducible method for ctDNA analysis in plasma,
with good analytical sensitivities and speciﬁcities as well as
the possibility of evaluating the mutational load in plasma
for diagnostic and research purposes. Although tissue is
currently the preferred ﬁrst sample choice for EGFR testing,
the EGFRv2 test could be a valuable and convenient method
in situations in which ctDNA analysis is recommended,
especially for repeated longitudinal testing.
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